Pacer Advisors
RIGL icon

Pacer Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Pacer Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.09M Buy
114,386
+48,882
+75% +$1.64M 0.01% 767
2025
Q4 		$2.81M Sell
65,504
-11,976
-15% -$451K 0.01% 921
2025
Q3 		$2.2M Buy
+77,480
New +$2.32M 0.01% 1015
2025
Q2 		– Sell
-112,629
Closed -$2.03M – 3563
2025
Q1 		$2.03M Buy
+112,629
New +$2.29M ﹤0.01% 943
2021
Q2 		– Sell
-1,464
Closed -$50K – 1534
2021
Q1 		$50K Buy
1,464
+199
+16% +$7.88K ﹤0.01% 1436
2020
Q4 		$44K Buy
+1,265
New +$36.6K ﹤0.01% 1427
2018
Q4 		– Sell
-1,924
Closed -$62K – 938
2018
Q3 		$62K Buy
+1,924
New +$57.8K ﹤0.01% 1130

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pacer Advisors's RIGL Position: Q1 2026 in Review

Pacer Advisors increased its Rigel Pharmaceuticals (RIGL) stake by 75% in Q1 2026, buying an estimated $1.64M and bringing the position to 114,386 shares worth $3.09M. The position accounts for 0.01% of the portfolio, ranked #767.

Pacer Advisors first reported a position in RIGL in Q3 2018 and has held it in 7 quarters since. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Pacer Advisors held 114,386 shares of Rigel Pharmaceuticals worth $3.09M as of Q1 2026.
  • Pacer Advisors bought 48,882 Rigel Pharmaceuticals shares in Q1 2026, an estimated $1.64M.
  • Rigel Pharmaceuticals made up 0.01% of Pacer Advisors's portfolio in Q1 2026, its #767 holding.
  • Pacer Advisors first reported a position in Rigel Pharmaceuticals in Q3 2018 and has held it in 7 quarters since.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.